Year: 2023
Type: review
Abstract: Alzheimer's disease (AD) is the leading cause of dementia worldwide. Numerous biomarker studies have clearly demonstrated that AD has a long asymptomatic phase, with the development of pathology occurring at least 2 decades prior to the development of any symptoms. These pathological changes include a stepwise development of amyloid-β (Aβ) plaques, followed by tau neurofibrillary tangles and subsequently extensive neurodegeneration in the brain. In this review, we discuss the first class of drugs intended to be disease modifying to be approved by the US Food and Drug Administration (FDA) for AD-anti-Aβ monoclonal antibodies-and the scientific rationale with which they were developed.
Source: CNS Drugs
Authors: Solana Leisher, Adriana Bohorquez, Marcus Gay, Victoria Garcia, Renarda Jones, Dobri Baldaranov, Michael S. Rafii
Institution: University of Southern California
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,390
OpenAlex ID: W4384818993